C-Cure Clinical Trial

Inclusion Criteria: * Subject is ≥ 18 and \< 75 years old; * Subject has Heart Failure, New York Heart Association (NYHA) class II or class III with LVEF \> 15% and ≤ 40% as assessed by transthoracic echocardiography; * Subject has ischemic heart disease; * Subject has an identifiable (by transthoracic echocardiography) area of transmural scar within the left ventricle; * Subject is on optimal and stable medical therapy for more than 2 months; * Subject is willing and able to undergo an ICD implantation, prior to receiving C-Cure™ or already has an ICD implanted; * Subject agrees to comply with all follow-up evaluations; * Subject has been informed of the nature of the clinical trial and agrees to its provision and has provided written informed consent. Exclusion Criteria: * Subject has been treated with cell-based therapy; * Subject has myocardial revascularization by PCI or CABG within 2 months prior to enrolment; * Subject has had an MI within 2 months prior to enrolment; * Subject is planned for PCI, CABG or any cardiac surgery; * Subject has received a biventricular pacemaker within 6 month prior to enrolment; * Subject has moderate to severe aortic valve heart disease, aortic or mitral prosthetic valve; * Subject has a significant mitral valve insufficiency (Effective Regurgitant Orifice (ERO) \> 0.2 cm²) with possibility of mitral valve surgery; * Subject has left ventricular thrombus; * Subject has LV aneurysma or is a candidate for surgical aneurysmectomy; * Subject LV ventricular wall thickness is \< 5 mm in the target territory; * Subject has proven high grade atrioventricular block or sustained ventricular tachyarrhythmias; * Subject has an hemodynamically significant congenital heart disorder; * Subject has clinical evidence for infection or active malignancy; * Subject has known stable chronic kidney dysfunction with serum creatinine \> 2.5 mg/dL at two occasions during the screening period; * Subject has experienced severe adverse reaction/allergies to contrast agents; * Subject has atherosclerosis and/or tortuosity of the aorta, iliac or femoral arteries of a degree, that could impede or preclude the safe retrograde passage of the delivery catheter, in the judgment of the investigator; * Subject is on chronic immunosuppressive transplant therapy; * Subject had an autologous or allogenic bone marrow or peripheral stem cell transplant or prior solid organ transplantation; * Subject has a multisystem disease; * Subject has been tested positive for Human Immunodeficiency Virus (HIV 1 or HIV 2), Hepatitis B Virus (HBV), Hepatitis C (HCV) and/or syphilis; * Women of child bearing potential; * Subject has life expectancy \< 1 year from non heart failure related causes; * Subject suffers from morbid obesity (Body Mass Index (BMI) \> 40); * Subject has a recent history of alcohol or drug abuse; * Subject has any other surgical or medical condition that, in the judgment of the investigator might warrant exclusion or be contraindicated for safety reasons; * Subject is currently participating in another trial.